Cardiac Magnetic Resonance Imaging for the Assessment of the Myocardium After Doxorubicin-based Chemotherapy

Lunning, Matthew A.; Kutty, Shelby; Rome, Eric; Li, Ling; Padiyath, Asif; Loberiza, Fausto R.; Bociek, R. Gregory; Bierman, Philip J.; Vose, Julie M.; Armitage, Jamés O.; Porter, Thomas R.

doi:10.1097/coc.0b013e31829e19be

Cited by 55 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A mild increase in myocardial scaring was also observed. The authors concluded that cMRI and left atrial volume might be early markers of diastolic dysfunction and markers of myocardial fibrosis [40,41].…”

Section: Emerging Cardiac Monitoring Methodologiesmentioning

confidence: 98%

See 1 more Smart Citation

Cancer treatment-related cardiac toxicity: prevention, assessment and management

Fanous

Dillon

2016

Med Oncol

View full text Add to dashboard Cite

Cancer therapies, especially anthracyclines and monoclonal antibodies, have been linked with increased rates of cardiotoxicity. The development of some cardiac side effects happens over several months, and changes in ejection fraction can be detected long before permanent damage or disability occurs. Advanced heart failure could be averted with better and earlier detection. Methodologies for early detection of cardiac changes include stress echocardiograms, cardiac velocity measurements, radionuclide imaging, cardiac MRI and several potential biomarkers. Many agents have been described for prophylaxis of cardiac events precipitated by cancer therapy. Prophylactic use of beta-blockers and ACE inhibitors may be considered for use with trastuzumab in breast cancer as tolerated. Recovery of cardiac function is possible early after the injury from a cancer therapy. Late complications for coronary artery disease, hypertension and arrhythmia are underappreciated. Treatments for severe cancer therapy-related cardiac complications follow the existing paradigms for congestive heart failure and coronary artery disease, although outcomes for cancer patients differ from outcomes for non-cancer patients.

show abstract

Section: Emerging Cardiac Monitoring Methodologiesmentioning

confidence: 98%

“…cMRI is able to assess both the functional and structural components of the myocardium. In a prospective study of 81 childhood cancer patients [40], the primary finding was a significant increase in left atrial volume by cMRI. A mild increase in myocardial scaring was also observed.…”

Section: Emerging Cardiac Monitoring Methodologiesmentioning

confidence: 99%

Cancer treatment-related cardiac toxicity: prevention, assessment and management

Fanous

Dillon

2016

Med Oncol

View full text Add to dashboard Cite

show abstract

“…Cardio-oncology: Use of feature tracking for the diagnosis of chemotherapy-induced cardiomyopathy has been established in multiple studies[5,40]. In another study, Kowallick et al[41] used this technique to measure left atrial mechanics in 10 healthy controls, 10 patients with HCM and 10 patients with heart failure with preserved LVEF (HFpEF).…”

Section: Reference Values Of Ft-cmr For Normal and Diseased Patientsmentioning

confidence: 99%

Feature tracking cardiac magnetic resonance imaging: A review of a novel non-invasive cardiac imaging technique

Rahman

Sethi

Murtaza

et al. 2017

WJC

View full text Add to dashboard Cite

Cardiovascular disease is a leading cause of morbidity and mortality globally. Early diagnostic markers are gaining popularity for better patient care disease outcomes. There is an increasing interest in noninvasive cardiac imaging biomarkers to diagnose subclinical cardiac disease. Feature tracking cardiac magnetic resonance imaging is a novel post-processing technique that is increasingly being employed to assess global and regional myocardial function. This technique has numerous applications in structural and functional diagnostics. It has been validated in multiple studies, although there is still a long way to go for it to become routine standard of care.

show abstract

“…Of 10 non-Hodgkin's lymphoma patients with cardiac MRI before and 3 months after doxorubicin-based chemotherapy, 5 had a greater than 10% decreases in LV ejection fraction, and three had at least one new or progressive segment of gadolinium-delayed enhancement at follow-up [76]. Global circumferential strain was lower after chemotherapy, suggesting that MRI detected early functional changes [76]. Myocardial contrast enhancement increased by day 3 of anthracyclines, which predicted a decrease in LV ejection fraction at 28 days [77].…”

Section: Monitoring Chemotherapy-induced Cardiotoxicitymentioning

confidence: 99%

Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers

et al. 2014

View full text Add to dashboard Cite

In the US, children diagnosed with cancer are living longer, but not without consequences from the same drugs that cured their cancer. In these patients, cardiovascular disease is the leading cause of non-cancer-related morbidity and mortality. Although this review focuses on anthracycline-related cardiomyopathy in childhood cancer survivors, the global lifetime risk of other cardiovascular diseases such as atherosclerosis, arrhythmias and intracardiac conduction abnormalities, hypertension, and stroke also are increased. Besides anthracyclines, newer molecularly targeted agents, such as vascular endothelial growth factor receptor and tyrosine kinase inhibitors, also have been associated with acute hypertension, cardiomyopathy, increased risk of ischemic cardiac events and arrhythmias, and are summarized here. This review also covers other risk factors for chemotherapy-related cardiotoxicity (including both modifiable and non-modifiable factors), monitoring strategies (including both blood and imaging-based biomarkers) during and following cancer treatment, and discusses the management of cardiotoxicity (including prevention strategies such as cardioprotection by use of dexrazoxane).

show abstract

Cardiac Magnetic Resonance Imaging for the Assessment of the Myocardium After Doxorubicin-based Chemotherapy

Abstract: Our data suggests that cMRI has the ability to assess both early structural and functional myocardial changes in association with doxorubicin-based chemotherapy.

Cited by 55 publications

References 24 publications

Cancer treatment-related cardiac toxicity: prevention, assessment and management

Cancer treatment-related cardiac toxicity: prevention, assessment and management

Feature tracking cardiac magnetic resonance imaging: A review of a novel non-invasive cardiac imaging technique

Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers

Contact Info

Product

Resources

About